Signaling pathways in hepatocellular carcinoma

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 18-23

  Sia, Daniela ^a,c   Villanueva, Augusto ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hepatocellular carcinoma; Oncogene addiction; Signaling pathways; Sorafenib; Targeted therapy

Indexed keywords

CETUXIMAB; ERLOTINIB; GEFITINIB; GROWTH FACTOR; IMATINIB; SORAFENIB; TRASTUZUMAB; VEMURAFENIB;

ANGIOGENESIS; BREAST TUMOR; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; MELANOMA; MOLECULAR THERAPY; MORTALITY; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS HEPATITIS;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84855302023     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333254     Document Type: Review

References (46)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917. (Pubitemid 37518510)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
3. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576. (Pubitemid 46890874)
4. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442. (Pubitemid 36152543)
5. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
6. Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
7. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55-76.
8. Tovar V, Alsinet C, Villanueva A, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010;52:550-559.
9. Newell P, Toffanin S, Villanueva A, et al: Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009;51:725-733.
10. Villanueva A, Llovet JM: Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-1426.
11. Hanahan D, Weinberg R: The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
12. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL: The human disease network. Proc Natl Acad Sci USA 2007;104: 8685-8690. (Pubitemid 47175372)
13. Blasco RB, Francoz S, Santamaría D, et al: c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011;19:652-663.
14. Jain M, Arvanitis C, Chu K, et al: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-104. (Pubitemid 34743102)
15. Van't Veer LJ, Bernards R: Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008;452:564-570. (Pubitemid 351483370)
16. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
18. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;30:2507-2516.
19. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM: Experimental models of hepatocellular carcinoma. J Hepatol 2008;48:858-879.
20. Villanueva A, Chiang DY, Newell P, et al: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-1983.
21. Sangiovanni A, Del Ninno E, Fasani P, et al: Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004;126:1005-1014. (Pubitemid 38451172)
22. Sachdev D, Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12. (Pubitemid 46206663)
23. Tang SH, Yang DH, Huang W, Zhou HK, Lu XH, Ye G: Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res 2006;12:4171-4177.
24. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-449.
25. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E: Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997;25:862-866. (Pubitemid 27157127)
26. Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS: Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-1595.
27. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
28. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53. (Pubitemid 36331965)
29. Chiang DY, Villanueva A, Hoshida Y, et al: Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-6788.
30. Hoshida Y, Villanueva A, Kobayashi M, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
31. Tanabe KK, Lemoine A, Finkelstein DM, et al: Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008;299:53-60.
32. Calvisi DF, Ladu S, Gorden A, et al: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-1128.
33. Guertin DA, Stevens DM, Saitoh M, et al: mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15:148-159.
34. Li XM, Tang ZY, Zhou G, Lui YK, Ye SL: Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 1998;17:13-17. (Pubitemid 28215959)
35. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST: Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004;91:1354-1360. (Pubitemid 39331462)
36. Yoshiji H, Kuriyama S, Yoshii J, et al: Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002;35:834-842. (Pubitemid 34258377)
37. Mitsuhashi N, Shimizu H, Ohtsuka M, et al: Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003;37:1105-1113. (Pubitemid 36538687)
38. Campbell JS, Hughes SD, Gilbertson DG, et al: Platelet-derived growth factor C induces liver fibrosis, esteatosis and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005;102:3389-3394. (Pubitemid 40328055)
39. Elmileik H, Paterson AC, Kew MC: Beta-catenin mutations and expression, 249serine p53 tumor suppressor gene mutation, and hepatitis B virus infection in southern African Blacks with hepatocellular carcinoma. J Surg Oncol 2005;91:258-263. (Pubitemid 41266823)
40. Cui J, Zhou X, Liu Y, Tang Z, Romeih M: Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. J Gastroenterol Hepatol 2003;18:280-287. (Pubitemid 36519145)
41. Huang S, He J, Zhang X, et al: Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006;27:1334-1340. (Pubitemid 43985408)
42. Giovannini C, Lacchini M, Gramantieri L, Chieco P, Bolondi L: Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res 2006;26:2123-2127. (Pubitemid 43989479)
43. Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, Venturi A, et al: Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int 2007;27:997-1007. (Pubitemid 47261955)
44. Chappell WH, Green TD, Spengeman JD, McCubrey JA, Akula SM, Bertrand FE: Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle 2005;4:1389-1395. (Pubitemid 41437129)
45. Coulouarn C, Factor VM, Thorgeirsson SS: Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008;47:2059-2067. (Pubitemid 351945572)
46. Caja L, Bertran E, Campbell JS, Fausto N, Fabregat I: The transforming growth factor-beta (TGF-β) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J Cell Physiol 2011;226:1214-1223.